Molecular Therapeutics (MT) The goal of the Molecular Therapeutics (MT) Program is to identify therapeutic targets, drugs, and strategies, and to facilitate the translation of Dartmouth-investigator hypotheses into clinical trials. The research interests of the program faculty cover the full spectrum of investigations in molecular therapeutics and include synthesis of novel compounds as research tools and potential therapeutics; investigation of novel targets for therapy; assessment of predictors of disease progression or drug response; and proof-of-concept and therapeutic early phase clinical trials. The MT program currently has 30 members from 9 different departments whose research foci can be described under the following four scientific themes: (1) Synthesis and discovery of novel compounds and potential cancer drugs, (2) Interrogation of potential new targets and therapeutic strategies, (3) Development of biomarkers for cancer diagnosis and prediction of treatment response, and (4) Development of hypothesis-based cancer clinical trials. These four research themes do not exist as separate entities. There is extensive interaction between them, as novel drugs and compounds are used to interrogate novel targets, novel biomarkers are being identified, and these advances are being translated into molecular proof-of- principle clinical trials. The interactions across this spectrum are catalyzed by the interactive environment generated by activities of the MT program, its deep involvement in the Early Phase Trials Clinical Oncology Group (EPTCOG), and by the continual nurturing and mentoring of program members by the Program Co- Directors. This work results in extensive collaborations across the entire spectrum of molecular therapeutics, as evidenced by joint grants and publications. Major contributions of the program to the NCCC mission have been the facilitation of discoveries promising new therapeutic approaches, the translation of Dartmouth investigator hypotheses into clinical trials, and the accrual of patients to such studies. In addition, NCCC has made substantial commitment to improving the depth and breadth of research and clinical translation in the MT program through support of shared resources, financially supporting many of the costs associated with early- phase/proof-of-principle clinical trials, and strategic recruitment of new investigators. For example, over the past 5 years, the membership of the program has evolved with the successful recruitment of outstanding new faculty in the biological laboratory sciences (Miller, Kurokawa), chemistry (Micalizio, Wu), and in clinical/translational investigations (Danilov, Lansigan, Smith). More than 363 cancer-related articles have been published over the reporting period (54 [15%] in high impact journals), many of them representing intra- program (69=19%) or inter-program (107=29%) collaboration. These collaborations involve 29 MT program members and 63 NCCC members, almost equally distributed between the other 5 NCCC research programs. Total funding for the program currently is $8.0M, of which $6.0M is peer-reviewed and $3.4M is from NCI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA023108-39S5
Application #
9758117
Study Section
Subcommittee I - Transistion to Independence (NCI)
Program Officer
Belin, Precilla L
Project Start
Project End
2019-11-30
Budget Start
2017-12-01
Budget End
2018-11-30
Support Year
39
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Dartmouth College
Department
Type
DUNS #
041027822
City
Hanover
State
NH
Country
United States
Zip Code
Lin, Anping; Yin, Juan; Cheng, Chao et al. (2018) Decreased expression of FOXA2 promotes eutopic endometrial cell proliferation and migration in patients with endometriosis. Reprod Biomed Online 36:181-187
Elder, David E; Piepkorn, Michael W; Barnhill, Raymond L et al. (2018) Pathologist characteristics associated with accuracy and reproducibility of melanocytic skin lesion interpretation. J Am Acad Dermatol 79:52-59.e5
Rutter, Carolyn M; Kim, Jane J; Meester, Reinier G S et al. (2018) Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. Cancer Epidemiol Biomarkers Prev 27:158-164
Kumar, Nishant; Tafe, Laura J; Higgins, John H et al. (2018) Identifying Associations between Somatic Mutations and Clinicopathologic Findings in Lung Cancer Pathology Reports. Methods Inf Med 57:63-73
Punshon, Tracy; Jackson, Brian P (2018) Essential micronutrient and toxic trace element concentrations in gluten containing and gluten-free foods. Food Chem 252:258-264
Pernas, Sonia; Martin, Miguel; Kaufman, Peter A et al. (2018) Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. Lancet Oncol 19:812-824
Svedbom, Axel; Borgström, Fredrik; Hernlund, Emma et al. (2018) Quality of life after hip, vertebral, and distal forearm fragility fractures measured using the EQ-5D-3L, EQ-VAS, and time-trade-off: results from the ICUROS. Qual Life Res 27:707-716
Skolasky, Richard L; Scherer, Emily A; Wegener, Stephen T et al. (2018) Does reduction in sciatica symptoms precede improvement in disability and physical health among those treated surgically for intervertebral disc herniation? Analysis of temporal patterns in data from the Spine Patient Outcomes Research Trial. Spine J 18:1318-1324
Doubeni, Chyke A; Gabler, Nicole B; Wheeler, Cosette M et al. (2018) Timely follow-up of positive cancer screening results: A systematic review and recommendations from the PROSPR Consortium. CA Cancer J Clin 68:199-216
Sites, Brian D; Harrison, Jordon; Herrick, Michael D et al. (2018) Prescription Opioid Use and Satisfaction With Care Among Adults With Musculoskeletal Conditions. Ann Fam Med 16:6-13

Showing the most recent 10 out of 1911 publications